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Abstract
The chromosomal translocation (11;14)(q13;q32) rearranging the locus for cyclin D1 (CCND1) to that of the
immunoglobulin heavy chain (IGH) can be found in virtually all cases of mantle cell lymphoma (MCL), while other
CCND1 translocations are extremely rare. As CCND1 overexpression and activation is a hallmark of MCL it is
regarded as a central biological mechanism in the development and maintenance of this disease.
Here we present a patient initially diagnosed with chronic lymphocytic leukemia (CLL) where chromosome
banding analysis revealed, among other aberrations, a translocation (11;22)(q13;q11.2). We show by fluorescence in
situ hybridization (FISH) analysis that on chromosome 22 the immunoglobulin light chain lambda (IGL) is involved
in this cytogenetic aberration. Additionally, we demonstrate the resulting overexpression of CCND1 on the RNA
and protein level, thereby consolidating the new diagnosis of a MCL-like B-cell neoplasia. Summing up, we
described a rare case of t(11;22)(q13;q11.2) in a MCL-like neoplasia and showed that this aberration leads to an
overexpression of CCND1 which is regarded as a key biological feature in MCL. This case underlines the importance
of cytogenetic analyses especially in atypical cases of B cell lymphomas.
Background
Mantle cell lymphoma (MCL) and chronic lymphocytic
leukaemia (CLL) belong to the group of CD5-positive
small B-cell neoplasms. While CLL is the most common
leukaemia in western countries with an incidence rate of
about 5 cases per 100,000, MCL is much less frequent
with a 10-fold lower incidence rate of about 0.5 cases
per 100,000 [1]. CLL and MCL share a distinct set
of overlapping morphological features and clinical
manifestation making it difficult in given situations to
distinguish both diseases. Besides flow cytometric
immunophenotyping, cytogenetic analysis is a deciding
factor to discriminate between both entities. A promi-
nent marker for MCL is the translocation (11;14)(q13;
q32), resulting in a rearrangement of the gene loci for
immunoglobulin heavy chain (IGH) on chromosome 14
and cyclin D1 (CCND1) on chromosome 11. This leads
to a constitutional overexpresion of CCND1 due to the
IGH enhancer sequence located in front of CCND1 [2].
Cyclin D1 is a cell cycle regulator usually transiently
expressed in cells. Its aberrant overexpression in MCL
leads to a high mitotic rate of the affected B-cells [3].
Other translocations resulting in an increased CCND1
gene expression are extremely rare [4-6].
In CLL cytogenetic studies focus on fluorescence in-
situ-hybridization (FISH) analyses for trisomy 12, dele-
tion of 6q, 11q, 13q and 17p, although about 30% of
CLL cases show non-recurrentt r a n s l o c a t i o n s[ 7 ] .T h e
lack of mitotic CLL cells under culture conditions has
largely been limiting the use of other chromosome ana-
lysis techniques. Recently, the use of new stimulating
substances like CpG-oligonucleotide DSP-30 and Inter-
leukin-2 resulted in an increase of proliferating CLL
cells in culture and remarkably improved the success
rate of classical chromosome analysis in CLL diagnostics
[8-10]. Since then many cases of CLL where reported
showing atypical and rare chromosomal aberrations,
making the distinction borders to other B-cell malignan-
cies blurry [11,12].
Despite these significant improvements, flow cyto-
metric immunophenotyping remains the most important
diagnostic tool for diagnosis of different B-cell neo-
plasms. While bright expression of FMC-7 and surface
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absent in CLL, the surface marker CD23 is typically
found on CLL cells, but not MCL cells. Cases of CLL
with variant phenotypes negative for CD23 and/or posi-
tive for FMC-7 usually are tested for t(11;14)(q13;q32)
to eliminate the possibility of misdiagnosing MCL [13].
Since the clinical course of MCL is very aggressive with
an overall survival of 3 to 5 years, all possible efforts for
distinguishing CLL from MCL should be done.
Case presentation
In March 2010 we received peripheral blood (PB) from a
60 year old woman initially diagnosed with CLL in the
context of a clinical CLL trial. The patient was thera-
peutically naive and exhibited an initial lymphocyte
count of 22 × 10
6/ml. By cell morphology a blastoid
MCL variant could be excluded. Clinically, a general
lymphadenopathy but no B symptoms were present. So
far the disease developed slowly over 24 months sug-
gesting an intermediate progressive course. The IgVH
status was mutated. Unfortunately, no bone marrow or
lymph node biopsy was available for further analysis.
Materials and methods
Flow cytometry
Five-color flow cytometric analysis was performed on a
FC500 instrument (Beckman Coulter, Brea/CA, USA) as
described by Costa et al. [14]. The following antibodies
were used: CD19-ECD, CD5-FITC, CD10-PE, CD23-
FITC, FMC7-FITC, CD79b-PE (Beckman Coulter, Brea/
CA, USA) and polyclonal rabbit anti-human lambda
light chains, rabbit F(ab’)2 PE-conjugated (DAKO,
Glostrup, Denmark).
Chromosome analysis
Peripheral blood was cultured for 96 hours in Marrow-
Max medium (Invitrogen, Grand Island/NY, USA). Two
cultures with different mitogens were used: 12-O-tetrade-
canoylphorbol-19-acetate (Sigma-Aldrich, St. Louis,
USA) and CpG-oligonucleotide DSP30 (TIB MOLBIOL,
Berlin, Germany) plus Interleukin 2 (Biochrom, Berlin,
Germany). Chromosome analysis was performed on tryp-
sin giemsa banded chromosome preparations and karyo-
types were interpreted according to the ISCN 2009 [15].
Fluorescence in-situ-hybridization (FISH)
Interphase FISH was performed with a commercial set of
probes consisting of 13q14/13q34 (D13S25, D13S319/
13q34), 11q22/11cen (ATM/D11Z1), 6q23/6cen (MYB/
D6Z1), 17p13/17cen (TP53/D17Z1) and centromere 12
(D12Z3) (MetaSystems, Altlussheim, Germany). Addi-
tionally, dual-color, dual-fusion translocation probes for
CCND1/IGH and for BCR/ABL were used (MetaSystems,
Altlussheim, Germany). The gene rearrangement
involving IGL was assessed using an IGL dual-color,
breakapart probe (MetaSystems, Altlussheim, Germany).
The CCND1/IGL translocation was analysed with a tri-
color, dual fusion probe consisting of a CCND1 dual
color, break-apart probe (Abbott Molecular, Downers
Grove, IL) and a homebrew IGL probe labeled in Spec-
trum Aqua (CTA-526G4, CTA-60B5, CTA-865E9).
Interphase and metaphase FISH analysis was performed
according to the manufacturer’s instructions.
Multicolor FISH (mFISH) was performed on meta-
phase spreads using the 24XCyte MetaSystems Chromo-
some painting kit according to the manufacturer’s
instructions (MetaSystems, Altlussheim, Germany).
Immunobloting
Cells were lysed with MPER Mammalian Extraction
Reagent (Thermo Scientific, Rockford/IL, USA) includ-
ing DTT on ice for 60 minutes. Protein concentration
was measured by Bradford assay. Solubilised proteins
were resolved by PAGE and transferred onto a nitrocel-
lulose membrane (Invitrogen, Karlsruhe, Germany).
Blots were probed with monoclonal mouse anti-human
cyclin D1 antibody (BD Biosciences, Franklin Lakes/NJ,
USA), monoclonal mouse anti-ß-actin antibody (Sigma-
Aldrich, USA) and a polyclonal goat anti-mouse peroxi-
dase-conjugated secondary antibody (Dako, Denmark).
Antibody binding was detected using Amersham ECL™-
Western blotting detection reagents (GE Healthcare UK
Limited, Buckinghamshire, UK). The well-characterized
MCL cell line GRANTA-519, which features the t
(11;14)(q13;q32), hence shows a high expression of
cyclin D1 protein [16] served as a positive control.
Quantitative real-time RT-PCR
For quantitative real-time RT-PCR, total RNA from the
patient and GRANTA-519 cells was purified using
QIAmp RNA Blood Mini Kit (Qiagen, Hilden, Germany)
and cDNA synthesis was subsequently done applying
First Strand cDNA Synthesis Kit (Roche, Grenzach-
Wyhlen, Germany). The expression status of cyclin D1
(CCND1) was monitored using TaqMan© Probe real-
time PCR assay with LightCycler© FastStart DNA
MasterPLUS HybProbe Kit (Roche, Grenzach-Wyhlen,
Germany) on a LightCycler© 480 Instrument. For ampli-
fication of CCND1,f o r w a r dp r i m e r5 ’-AGTGCAAG-
GCCTGAACCTG-3’, reverse primer 5’-GGCAGTC
TGGGTCACACTTGA-3’ and the probe 5’-6FAM-
TTCCTGTCCTACTACCGCCTCACACGCTTC-Dab-
cyl-3’ were applied with a standard PCR cycling profile
of 45 cycles and an annealing temperature of 60°C. Tar-
get gene expression was normalized against the expres-
sion of the housekeeping gene ABL1 with primers and a
probe as previously described [17] and target gene
expression values are given as %CCND1/ABL1 with
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Results
Flow cytometric analysis showed a positive population
for CD5, FMC-7, CD79b and surface Ig lambda but
negativity for CD10 and low CD23 (Figure 1). This
immunophenotype was more consistent with a MCL
than with CLL. Morphology on peripheral blood smears
showed no smudge or basket cells which are typical for
CLL patients. Instead lymphoid cells with irregular
nuclear contours were seen, fitting the antecedent suspi-
cion of MCL (Figure 2). For further confirmation of the
supposed MCL a FISH for t(11;14)(q13;q32) was per-
formed. Surprisingly, the rearrangement of IGH and
CCND1 could not be confirmed, but an additional signal
for 11q13 was observed in 78% of analysed cells (Figure
3a). Two constellations were possible: Trisomy 11 or
translocation of chromosome 11 involving the CCND1
gene. Chromosome analysis showed two different clones,
both with a trisomy 3 and a translocation t(11;22)(q13;
q11.2), proving the second constellation to be true. Kar-
yotype was confirmed via mFISH and described as 47,
XX, +3, t(11;22)(q13;q11.2) [16]/46, X, der(X)t(X;1)
(p22.1;p21), del(1)(p21), +3, der(8)t(8;17)(p21;q21),
t(11;22)(q13;q11.2),-17,2~9dmin [4] (Figure 4 and 5).
Further analysis applying our routinely used CLL
FISH-panel showed a normal signal pattern for 6q23/
6cen, 13q14/13q34, and centromere 12. Interphase FISH
for 11q22/11cen had a normal signal pattern, whereas
on metaphases the translocation t(11;22) could be con-
firmed, given that signal for 11q22 and for 11 centro-
mere were localized on different chromosomes (data not
shown). Interphase and metaphase FISH for 17p13/
17cen were aberrant on cells with the complex clone
showing one signal for 17p13 (aberrant in 10% of ana-
lysed interphases), well-fitting the unbalanced transloca-
tion t(8;17) with loss of 17p (data not shown).
To determine the translocation partner gene for
CCND1 on chromosome 22 three different FISH probes
were used: one dual-color, dual-fusion probe for BCR/
ABL, a dual-color, breakapart IGL probe and a tri-color,
dual fusion CCND1/IGL probe. The BCR/ABL probe
showed a normal signal pattern (data not shown)
whereas the IGL probe showed a break in one IGL gene
locus in 84% of analysed cells (Figure 3b). FISH analysis
with the CCND1/IGL tri-color, dual fusion probe could
clearly show the CCND1/IGL translocation on 78% of
analysed interphases and also on metaphases (Figure 3c).
As investigated by quantitative real-time RT-PCR, an
overexpression of CCND1 could be clearly detected for
the patient (%CCND1/ABL1 = 144,45) compared to
Figure 1 Flow cytometry results. Flow cytometric graphs showing positivity for CD5, CD79b, FMC7, surface immunoglobulin lambda and
negativity for CD23 and CD10.
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(%CCND1/ABL1 = 146,85). Only a minimal expression
of CCND1 (%CCND1/ABL1 = 0,37) could be detected
for the negative control (Figure 6). In conformity with
those findings, western blot analysis of cyclin D1 protein
showed a remarkably overexpression (Figure 7).
Discussion
In general the vast majority of MCL patients show a
translocation (11;14)(q13;q32) leading to an IGH/CCND1
gene rearrangement. Atypical translocations involving
CCND1 and immunoglobulin kappa chain (Igk) also lead-
ing to an overexpression of cyclin D1 have been reported
[18]. IGL translocations were found in different neo-
plasms, e.g. t(18;22) leading to BCL2 to IGL rearrangement
in a case of CLL [19] or c-MYC to IGL rearrangement in
Burkitt’s lymphoma [20]. Komatsu et al. [4] reported on a
MCL case showing an atypical rearrangement t(11;22)
(q13;q11). They first speculated this translocation might
result in a rearrangement of CCND1 to the IGL gene
locus and confirmed their hypothesis on molecular level in
a subsequent publication [21]. The WHO classification
points to the possibility of this rare translocation, referring
to aforementioned work [22].
In our case we investigated the affected gene on chro-
mosome 22 involved in the t(11;22) and therefore respon-
sible for the cyclin D1 overexpression, possibly leading to
the development of an MCL. A FISH analysis with a BCR/
ABL probe was performed, due to the localization of BCR
on 22q11 and different reports showing atypical cases of
BCR translocations to e.g. FGFR1 or PDGFRA genes
[23,24]. As we found a normal signal pattern for BCR/ABL
and therefore excluded the involvement of BCR to the
translocation on chromosome 22 we assumed an involve-
ment of IGL.F I S Ha n a l y s i sa st h em e t h o do fc h o i c ef o r
proving IGL involvement has already been reported for
different chromosome 22 translocations [25]. Thus, our
FISH analysis with a CCND1/IGL probe could prove the
fusion of CCND1 to IGL concordantly to the findings by
Komatsu et al [4,21]. Furthermore, we could show the
cyclin D1 overexpression on mRNA and protein level,
consolidating the diagnosis of a MCL-like neoplasia.
Analysis on GTG banded chromosome preparations
revealed two different aberrant clones. The dominant
clone, presumably the mainline, revealed an additional
chromosome 3 and the translocation between
Figure 2 Morphology of patient’s leukaemic cells. Medium-sized
lymphoid cell with lightly basophilic cytoplasm and medium-sized
irregular nucleus with dispersed chromatin.
Figure 3 Metaphase and interphase FISH. (a) FISH showing 3 signals for CCND1 due to a translocation at the CCND1 locus on 11(q13). CCND1
on 11(q13) is marked in red, IGH on 14(q32) is marked in green. (b) FISH confirming IGL rearrangement with an IGL dual-color breakapart probe.
Broad arrows show separated signals for the IGL proximal region in red and for the distal region in green. The open arrow shows a fusion signal
for the normal chromosome 22. (c) FISH with a CCND1/IGL tri-color, dual-fusion probe, showing the IGL/CCND1 translocation. CCND1 on 11(q13)
marked in Spectrum Orange and Spectrum Green, IGL on 22(q11.2) marked in Spectrum Aqua. The broad arrow shows the derivative
chromosome 22 and the open arrow the derivative chromosome 11.
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ferent additional secondary abnormalities affecting chro-
mosomes X, 1, 8 and 17. As reported before, CCND1
translocations normally are considered as the primary
cytogenetic event in MCL. Secondary events are seen in
up to 88% of MCL cases, often involving trisomy 3,
breaks in 1p21 and 17p deletions among others [26], in
conformity with our findings in this case. The discovery
of double minutes (DM) was quite surprising, as double
minutes are very rare in lymphatic neoplasms. DM are
acentric extrachromosomal chromatin which may lead
to an amplification of oncogenes, like c-MYC amplifica-
tion in colorectal carcinoma [27]. Unfortunately, there
was no investigation material left for further analyzing
the DM, e.g. by array-CGH to finally clarify the source
of this additional genetic material.
Conclusions
Our patient was first suspected to have a CLL. We
could show, that the t(11;22)(q13;q11.2) leads to an
overexpression of cyclin D1 due to the rearrangement of
CCND1 to IGL. In addition immunophenotype and mor-
phology of the cells showed a typical MCL configuration.
However, some cases of t(11;14) positive CLL [9] and on
the other hand t(11;14) negative MCL have been reported
[28]. Cyclin D1 is usually overexpressed in MCL, but also
overexpression of cyclin D2 or cyclin D3 may induce a
MCL [5]. In general, B-cell neoplasms carrying rare trans-
locations involving CCND1 and Ig kappa or Ig lambda,
like reported here, are diagnosed as MCL. A distinction
between indolent and common cases of MCL has been
proposed lately by Fernandez et al. [29]. On the other
hand cyclin D1 overexpression in three cases with an IGK-
CCND1 rearrangement have been diagnosed as small-cell
B-non-Hodgkin lymphoma, as they did not show typical
features of MCL [18]. In our case we could show some
typical features of a MCL like a CCND1 translocation,
recurrent secondary chromosomal aberrations and cyclin-
D1 overexpression. But also some atypical features were
found like the existence of double minutes and mutated
Figure 4 Conventional chromosome analysis. Complex aberrant karyogram of patient showing the karyotype 46, X, der(X)t(X;1)(p22.1;p21), del
(1)(p21), +3, der(8)t(8;17)(p21;q21), t(11;22)(q13;q11.2), -17, 3dmin.
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the balanced translocation (11;22), the loss of one chromosome 17 and the unbalanced translocation (X;1).
Figure 6 Quantitative real-time RT-PCR results.T h e
overexpression of CCND1 could be clearly detected for the patient
in comparison to GRANTA-519 CCND1-positive cells. Expression
ratios are given as %CCND1/ABL1 in log-scale on the y axis.
Figure 7 Western blot analysis of CCND1 expression.T h e
overexpression of cyclin D1 in our patient is clearly visible (left
panel) as well as in GRANTA-519 cells with t(11;14)(q13;q32) (middle
panel) compared to a healthy donor (right panel).
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a MCL-like B-cell neoplasia.
Summing up, we described a third case of a t(11;22)(q13;
q11.2) leading to a rearrangement of CCND1 to IGL and
showed that this aberration leads to an overexpression of
CCND1 which is regarded as a key biological feature of
MCL. This case underlines the importance of cytogenetic
analyses especially in atypical cases of B cell lymphomas.
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